Recently, DNA methylation and reduced expression of the suppressor of the cytokine signaling-3 (SOCS3) gene in human hepatocellular carcinoma (HCC) patients have been reported. However, the roles of SOCS3 in HCC development in vivo have not been clarified. Using RT-PCR analysis and Western blotting, we confirmed that SOCS3 expression was reduced in HCC patients. However, reduced expression of SOCS3 occurred not only in HCC but also in nontumor regions, and this reduction was stronger as the fibrosis grade increased. Furthermore, SOCS3 levels were inversely correlated with signal transducers and activators of transcription-3 (STAT3) activation as well as transforming growth factor (TGF)-b1 levels in the non-HCC region. To define the molecular consequences of SOCS3 silencing/STAT3 hyperactivation and liver fibrosis, we examined liverspecific SOCS3-deficient mice. We demonstrated that SOCS3 deletion in the liver resulted in hyperactivation of STAT3 and promoted ConA-and chemical-induced liver fibrosis. The expression of TGF-b1, a mediator of fibrosis, was enhanced by SOCS3 gene deletion, but suppressed by the overexpression of a dominant-negative STAT3 or SOCS3 both in vivo and in vitro. These data suggest that TGF-b1 is a target gene of STAT3 and could be one of the mechanisms for enhanced fibrosis in SOCS3-deficient mice. Thus, our present study provides a novel role of SOCS3 and STAT3 in HCC development: in addition to the previously characterized oncogenic potentials, STAT3 enhances hepatic fibrosis through the upregulation of TGF-b1 expression, and SOCS3 prevents this process.
Introduction
Most hepatocellular carcinomas (HCCs) develop as a result of liver cirrhosis and advanced fibrosis. IL-6 has been implicated in the promotion of inflammation, fibrosis, and carcinogenesis in the liver. This is because high levels of IL-6 induce hepatic inflammation, collagen synthesis, tissue inhibitor of metalloproteinase-1 (TIMP1) expression, and early transition of stellate cells (also called Ito cells and lipocytes) into myofibroblasts in mice (Choi et al., 1994) . Hyperactivation of the signal transducers and activators of transcription-3 (STAT3), which is a downstream of IL-6/gp130, has been reported in HCC (Yoshikawa et al., 2001) . STAT3 is believed to contribute to cell proliferation and antiapoptosis by inducing c-myc, cyclin-D1, and Bcl-XL and, therefore, functions as an oncogene (Bromberg et al., 1999; Bromberg and Darnell, 2000) . Recently, STAT3 was shown to induce the vascular endothelial growth factor (VEGF), which contributes to tumor-associated angiogenesis. Furthermore, STAT3 suppresses the tumor expression of proinflammatory cytokines and chemokines, resulting in the reduced activation of antitumor immunity (Wang et al., 2004) . Therefore, STAT3 is deeply involved in HCC development by multiple mechanisms (Wei et al., 2003) . STAT3 is activated not only by IL-6 and related cytokines, but also by direct interaction with the hepatitis C virus (HCV) core protein in the liver (Yoshida et al., 2002) .
Cytokines, including IL-6, activate the Janus kinase (JAK)/STAT signaling pathway, which plays a vital role in various conditions, including immune reaction, cell growth, and differentiation. Cytokine signaling is strictly regulated by suppressor of the cytokine signaling (SOCS) family proteins. Among them, SOCS1 is relatively specific to STAT1, and SOCS3 to STAT3 (Kinjyo et al., 2002; Croker et al., 2003; Yasukawa et al., 2003) . SOCS1 inhibits JAK activation through its Nterminal kinase inhibitory region (KIR) by direct binding to the activation loop of JAKs, while SOCS3 inhibits JAK kinase by binding to the cytokine receptors through its SH2 domain. Furthermore, the SOCS box, another domain in SOCS proteins, is able to interact with Elongins B and C and couples the SH2 domain-binding proteins to the ubiquitin-proteasome pathway (Kamura et al., 1998; Kamizono et al., 2001) . Therefore, SOCS1 and SOCS3 inhibit cytokine signaling by suppressing JAK kinase activity and promoting the degradation of the activated cytokine receptor complex. SOCS1 induction is restricted to interferons and some other cytokines, while SOCS3 is induced by a variety of stimuli, such as interleukins, interferons, and TNFa (Bode et al., 1999; Yasukawa et al., 2003; Kamio et al., 2004) . However, since binding of the SH2 domain of SOCS3 is relatively specific to the receptors for STAT3-activating cytokines, such as IL-6, G-CSF, and leptin, the effect of SOCS3 may be relatively restricted to STAT3 (Croker et al., 2003 (Croker et al., , 2004 Mori et al., 2004) .
In connection with SOCS and HCC, the SOCS1 gene has been implicated as an antioncogene for HCC development. Yoshikawa et al. (2001) reported aberrant methylation in the CpG island of SOCS1 that correlated with its transcriptional silencing in HCC cell lines. In support of this, a recent experiment has shown that SOCS1 heterozygous mice are hypersensitive to diethylnitrosamine (DEN)-induced hepatocarcinogenesis . A simple explanation is that STAT3 hyperactivation is the result of reduced expression of SOCS1 by DNA methylation, which leads to hyperproliferation and antiapoptosis of hepatocarcinoma cells. However, the effect of SOCS3 deletion on STAT3 hyperactivation has not been demonstrated in vivo, and, as we reported, STAT3 is mostly regulated by SOCS3 rather than SOCS1 (Kimura et al., 2004; Mori et al., 2004) . Recently, reduced expression of SOCS3 and aberrant methylation in the CpG island of the SOCS3 locus in HCC patient samples and cell lines have been reported (Niwa et al., 2005) . These researchers also reported that SOCS3 negatively regulates cell growth and cell motility by inhibiting STAT3 and FAK signalings in cultured HCC cell lines. However, the effect of SOCS3 gene silencing in the liver in HCC development and STAT3 activation has not been established in vivo.
In this study, using RT-PCR and Western blotting, we confirmed that the expression of SOCS3 was reduced in the liver of human HCC patients. However, the reduction of SOCS3 expression was observed not only in HCC regions but also in non-HCC regions. SOCS3 expression levels were inversely correlated with STAT3 activation and fibrosis. Thus, we investigated the role of SOCS3 in liver fibrosis using liver-specific SOCS3-deficient mice. We demonstrated that STAT3 hyperactivation promoted chemical compound-and concanavalin-A (ConA)-induced liver fibrosis. Part of this mechanism is explained by the transcriptional induction of transforming growth factor (TGF)-b1, an essential mediator of fibrosis, through STAT3. These findings suggest that SOCS3 contributes to the suppression of HCC development by protecting the liver cells against hepatic fibrosis mediated by TGF-b1. Our study also provides a basis for the therapeutic potential of liver cirrhosis/HCC by STAT3 antagonists.
Results
Correlation between STAT3 activation, SOCS expression, and fibrosis in human HCC We investigated the correlation between STAT3 activation and the expression levels of SOCSs in HCC and noncancerous tissues in human patients. As reported, we confirmed that both SOCS1 and SOCS3 mRNA levels were lower in the HCC region than in the nontumor region (data not shown). However, we noticed that the SOCS3 expression levels in the non-HCC region were variable and often very low in samples with severe fibrosis. Therefore, we compared the correlation between fibrosis and STAT3 activation and SOCS3 expression in non-HCC regions. We also examined the levels of TGF-b1, an essential mediator of fibrosis (Nakamura et al., 2000) . The progression of liver fibrosis was classified into four stages, from F1 to F4, as judged by histological examination (Bedossa and SOCS3 regulates hepatic fibrosis and TGF-b1 H Ogata et al Poynard, 1996) . As shown in Figure 1a , the TGF-b1 mRNA levels, determined by real-time RT-PCR, were well correlated with the fibrosis grade. As expected, the SOCS3 mRNA ( Figure 1b ) and protein ( Figure 1c ) levels, as determined by Western blotting, decreased as the fibrosis grade increased. Furthermore, the activation of STAT3 increased as the fibrosis grade increased (Figure 1c and d) . These data suggest that the SOCS3 levels were inversely correlated with liver fibrosis, TGFb1 expression, and STAT3 activation.
Generation of liver-specific SOCS3-deficient mice To demonstrate that the reduction of SOCS3 gene expression causes STAT3 activation and TGF-b1 expression, we investigated experimental liver fibrosis models using liver-specific SOCS3 knockout (KO) and SOCS3 þ /À mice. Since SOCS3-deficient mice die as a result of placental defects during embryonic development (Roberts et al., 2001 ), a conditional KO approach has been used to determine the tissue-specific roles of SOCS3 (Yasukawa et al., 2003) . To generate a liver-specific deletion, SOCS3 flox/flox(fl/fl) mice were intravenously (i.v.) injected with an adenovirus carrying Cre-recombinase (AdCre) (Figure 2a and b) . SOCS3 gene deletion was specific to the liver and did not occur in other tissues, including the brain, heart, kidney, fat, and muscle (Figure 2c ). The AdCre-mediated SOCS3 deletion in the liver continued for more than 7 weeks (Figure 2c ). SOCS3 deletion in the liver did not occur when a control adenovirus carrying LacZ (AdLacZ) was injected. In the AdCre-treated mice, the SOCS3 gene was deleted in both the parenchymal and nonparenchymal cells (Figure 2d ).
SOCS3 deficiency in the liver promotes chemical compound-induced liver fibrosis Administration of dimethylnitrosamine (DMN) is a well-established chronic liver fibrosis model in mice. An intraperitoneal injection of a small amount of DMN has been shown to induce fatty degeneration of hepatocytes, activation and proliferation of hepatic stellate cells, infiltration by macrophages, and secretion of TGF-b1 from various types of cells, which promotes fibrosis. DMN was intraperitoneally (i.p.
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SOCS3 regulates hepatic fibrosis and TGF-b1
H Ogata et al DMN administration were higher than those in wildtype or control mice, suggesting that severe liver damage occurred by SOCS3 haploinsufficiency or complete deletion (Figure 3a and b). DMN treatment resulted in tissue remodeling with matrix deposition mainly in the centrilobular area and portal tract, as assessed histologically. a-Smooth muscle actin (SMA) localized mainly around the centrilobular area and the portal tract in the liver. Hepatic collagen deposition was stained with Sirius red and quantitated using digital image analysis (Figure 3c and d). At 7 weeks after DMN treatment, SMA and Sirius red stainings were much stronger in SOCS3 þ /À or AdCre-SOCS3 fl/fl mice than in control mice (Figure 3c ). The histological fibrosis score (Sirius red staining) as well as the amount of total collagen and serum hyaluronic acid levels were greater in SOCS3
þ /À mice and AdCre-SOCS3 fl/fl mice than in wild-type and control mice (Figure 3c and d). The expression levels of TGF-b1 were also significantly higher in SOCS3 þ /À mice and AdCre-SOCS3 fl/fl mice than in control mice ( Figure 3e ). Hepatic SOCS3 mRNA levels in SOCS3 þ /À mice were about half of those in SOCS3 þ / þ mice, and SOCS3 mRNA levels in AdCre-SOCS3 fl/fl mice were greatly reduced, while SOCS1 mRNA levels were not significantly different among these mice ( Figure 3e ). These data indicate that a reduced expression of SOCS3 exacerbated DMNinduced liver injury and fibrosis.
Then, we examined STAT3 phosphorylation in DMN-treated livers. Phosphorylated STAT3 was accumulated in the nucleus of both parenchymal and nonparenchymal cells in DMN-treated livers (Figure 3f ). STAT3 phosphorylation was greater in SOCS3 þ /À and AdCre-SOCS3 fl/fl mice than in control mice, as confirmed by both immunohistochemistry and immunoblotting (Figure 3f and g ). On the other hand, the STAT1 and ERK phosphorylation levels were not significantly different (Figure 3g ). These data raise the possibility that reduced expression of the SOCS3 gene exacerbated DMN-induced liver fibrosis through hyperactivation of STAT3, which induces the upregulation of fibrosis-and remodeling-related genes such as TGF-b1. SOCS3 deficiency in the liver promotes ConA-induced liver fibrosis ConA-induced hepatitis also develops fibrosis after repeated liver injury, the mechanism of which is mainly based on the upregulation of TGF-b1 expression in the liver. Since ConA activates NK and NKT cells in the liver, ConA-induced fibrosis in mice has been used as a suitable model of viral hepatitis and fibrosis like human HCV infection. At 4 weeks after ConA treatment, the serum ALT levels were slightly elevated in AdCre-SOCS3 fl/fl mice but not in control mice; however, the difference was not statistically significant. Therefore, ConA induced similar liver injury in both types of mice (Figure 4a ). However, fibrosis levels assessed by SMA and Sirius red staining were stronger in AdCre-SOCS3 fl/fl mice than in control mice (Figure 4b and c) . The amount of total collagen was also higher in AdCre-SOCS3 fl/fl mice than in control mice (Figure 4d ). We then examined STAT3 phosphorylation in ConA-treated livers. As shown in Figure 4b , higher levels of phosphorylated STAT3 were accumulated in the nucleus of both parenchymal and nonparenchymal cells in the livers of AdCre-SOCS3 fl/fl mice than in those of control mice. The expression levels of TGF-b1 were also significantly higher in AdCre-SOCS3 fl/fl mice than in control mice (Figure 4e ). SOCS3 protein and mRNA levels were severely reduced in AdCre-SOCS3 fl/fl mice (Figure 4b and e). These data indicate that reduced expression of SOCS3 exacerbated not only DMNinduced but also ConA-induced liver fibrosis and led to hyperactivation of STAT3 and enhanced TGF-b1 expression.
Blockade of STAT3 suppressed DMN-induced liver injury and fibrosis Next, we examined the effect of the suppression of STAT3 in TGF-b1 expression and liver fibrosis. SOCS3 and dominant-negative STAT3 (dnSTAT3) were overexpressed in the liver using adenoviruses carrying SOCS3 (AdSOCS3) and dnSTAT3 (AddnSTAT3). An injection of AdSOCS3 and AddnSTAT3, but not AdLacZ, significantly increased the survival of mice treated with DMN ( Figure 5a ) when a dose of DMN higher than that used in the experiments shown in Figure 3 was injected. Serum AST and ALT levels were also lower in mice injected with AdSOCS3 and AddnSTAT3 than in mice injected with AdLacZ (Po0.05) (Figure 5b ). Furthermore, a histological analysis with Sirius red, phosphorylated STAT3 (pY-STAT3), TGF-b1, and SMA staining, as well as with the amount of total collagen, clearly demonstrated that SOCS3 and dnSTAT3 overexpression strongly suppressed SMA expression (Figure 5c ), ameliorated hepatic fibrosis (Figure 5d ), and reduced collagen deposition (Figure 5c and e). The expression levels of TGF-b1, but not of SOCS1, were greatly suppressed by the SOCS3 and dnSTAT3 adenoviruses, but not by the LacZ control virus (Figure 5c and f). These data suggest that the blockade of STAT3 signaling suppressed DMN-induced chronic liver fibrosis and cirrhosis.
STAT3 upregulates TGF-b1 expression in liver cells
Our in vivo data suggest that TGF-b1 is upregulated by activated STAT3. However, the indirect effect on TGFb1 levels by liver damage, which is modulated by STAT3, cannot be excluded. To define the relationship between STAT3 and TGF-b1, we examined TGF-b1 mRNA levels in cultured hepatic cells in response to IL-6. Since primary hepatocytes can be isolated in large quantities and have the ability to produce a significant amount of TGF-b1 (Bissell et al., 1995) , we used primary hepatocytes first. IL-6 could be involved in the induction of TGF-b1, since the expression of TGFb1 was significantly reduced in IL-6-deficient mice (Natsume et al., 1999) . Real-time PCR analysis indicated that the TGF-b1 mRNA levels increased in response to IL-6. TGF-b1 induction in SOCS3-deficient hepatocytes was 2-3 times higher than that in WT SOCS3 regulates hepatic fibrosis and TGF-b1 H Ogata et al hepatocytes (Figure 6a ). On the other hand, the overexpression of a dominant-negative STAT3 (dnSTAT3) suppressed IL-6-induced TGF-b1 expression (Figure 6b ).
IL-6-mediated TGF-b1 induction was not inhibited by cycloheximide treatment (Figure 6c ), suggesting that activated STAT3 directly upregulates the transcription SOCS3 regulates hepatic fibrosis and TGF-b1 H Ogata et al 
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H Ogata et al of TGF-b1 mRNA. Similarly, IL-6 upregulated TGF-b1 mRNA levels in the human hepatoma cell line, HepG2 (Figure 6d) , and the human Ito cell line, LI90, and this upregulation was inhibited by dnSTAT3 or SOCS3 overexpression (Figure 6e) . From these data, we propose that TGF-b1 is a direct target of STAT3 and that SOCS3 negatively regulates TGF-b1 production by suppressing STAT3.
Discussion
HCC is believed to develop from liver cirrhosis and advanced fibrosis. In this study, we have shown that SOCS3 and STAT3 reciprocally regulate liver damages, fibrosis, and TGF-b1 expression induced by chemicals and ConA. Our data suggest that STAT3 directly upregulates TGF-b1 expression at the transcriptional 
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H Ogata et al levels. STAT3 is a well-characterized oncogene; it regulates gene expressions related to antiapoptosis, proliferation, neovascularization, and inflammation (Bromberg and Darnell, 2000; Wei et al., 2003; Wang et al., 2004) . Our study adds a new target, TGF-b1, to the list of STAT3-regulated genes involved in carcinogenesis. We have identified the two potential STAT3-binding sites in the promoter region of TGF-b1 and demonstrated that STAT3 activates the promoter activity in vitro (Kinjyo et al., unpublished data) . Therefore, TGF-b1 transcription seems to be directly regulated by STAT3. Furthermore, our study provides evidence for a unique feature of SOCS3 as an antioncogene: SOCS3 suppresses STAT3 activation and negatively regulates fibrosis in a precancerous stage in the liver. Our finding of a direct induction of TGF-b1 by active STAT3 may provide another mechanism of the contribution of STAT3 to carcinogenesis in addition to fibrosis (Factor et al., 1997; Bowman et al., 2000; Bissell, 2001) . TGF-b1 produced from tumor cells may induce T-cell inactivation, which causes an escape of tumor cells from immune surveillance (Gorelik and Flavell, 2001) . In this context, STAT3 is shown to suppress the expression of inflammatory cytokines and chemokines from tumor cells that attract lymphocytes and leukocytes to tumor cells (Wang et al., 2004) . Therefore, STAT3 activation may contribute to carcinogenesis by suppressing antitumor immunity through the upregulation of TGF-b1 and downregulation of inflammatory cytokines and chemokines.
Interestingly, STAT3 also regulates intracellular TGF-b1 signaling. Tumor cells are frequently resistant to the growth-inhibitory effect of TGF-b. One mechanism is the reduced expression of the TGF-b type II receptor in tumor cells (Markowitz et al., 1995; Saeki et al., 2000) . Indeed, the expression of the TGF-b type II receptor in the HCC region was greatly reduced compared with that in non-HCC region (Ogata et al., unpublished data). Another mechanism is the induction of Smad7, a negative-feedback regulator of TGF-b/ Smad signaling. Jenkins et al. (2005) recently reported that hyperactivation of STAT3 in mice carrying a mutant gp130, which lacked the SOCS3-binding site, promoted gastric adenomatous hyperplasia (Tebbutt et al., 2002) . Recently, they found that hyperactivation of STAT3 desensitized gastric cells to the cytostatic effect of TGF-b through the transcriptional induction of inhibitory Smad7 (Jenkins et al., 2005) . Therefore, STAT3 positively regulates both TGF-b and Smad7 Since the reduction of SOCS3 expression correlates with the progression of fibrosis in the non-HCC region in humans, SOCS3 may play a suppressive role in fibrosis and carcinogenesis in the liver. In many cases, both SOCS1 and SOCS3 were simultaneously downregulated in HCC (Niwa et al., 2005) . Like the SOCS1 gene, DNA methylation of the SOCS3 gene is found in several cancers, including HCC (He et al., 2003; Niwa et al., 2005; Weber et al., 2005) . However, the frequency of DNA methylation of the SOCS3 gene was not as high as that of SOCS1 in HCC (33% for SOCS3 and 65% for SOCS1) (Niwa et al., 2005; Yoshimura et al., 2005) . We found that the SOCS3 mRNA levels were lower in the HCC region than in non-HCC region in more than 90% of HCC patients (Ogata et al., unpublished data). Therefore, another mechanism, in addition to DNA methylation, must be present for the reduction of SOCS3 gene expression in human HCC.
It has not been identified what kind of cytokines are involved in STAT3 activation in ConA-or DMNtreated mice or in human HCC. It was reported that leptin, as well as IL-6, stimulates the activation of STAT3 and increases collagen mRNA expression in hepatic stellate cells and subsequently accelerates liver fibrogenesis (Saxena et al., 2002) . Therefore, these STAT3-activating cytokines must be promoting factors of liver fibrosis and carcinogenesis. While the growth hormone (GH) has also been reported to increase SOCS3 mRNA expression and to reduce the severity of fibrosis associated with chronic intestinal inflammation (Theiss et al., 2005) . GH-mediated suppression of fibrosis may be due to the inhibition of STAT3/TGF-b1 production by upregulated SOCS3.
Then, which type of cells play a major role in SOCS3/ STAT3-mediated TGF-b1 production and fibrosis? In our mice models, adenoviral vectors infected both parenchymal and nonparenchymal cells (Figure 2) . It has been shown that Ito cells are a major source of TGF-b1; however, a recent study suggests that parenchymal cells also produce significant amounts of TGF-b1 (Bissell et al., 1995) . We confirmed that IL-6-mediated upregulation of TGF-b1 mRNA levels was suppressed by overexpression of dnSTAT3 in both primary hepatocytes and an Ito cell line (Figure 6 ). Therefore, hyperactivation of STAT3 in both parenchymal and nonparenchymal cells in SOCS3-deficient mice may contribute to enhanced production of TGF-b1. DMN-induced liver damage was also enhanced in liverspecific SOCS3-deficient mice, but was suppressed in mice overexpressing SOCS3 or dnSTAT3 in the liver. We have not defined which type of cells would be important for liver damages in these models. Our preliminary data suggest that AlbCre-SOCS3 fl/fl mice, in which the SOCS3 gene was deleted only in parenchymal cells, were not sensitive and were rather resistant to DMN-induced liver injury (Ogata et al., unpublished data). Therefore, nonparenchymal cells, including lymphocytes, Kupffer cells, and stellate cells, may be important for enhanced liver damage in SOCS3-deficient mice. Further study is necessary to define the precise role of STAT3 in a different type of cells in the process of liver damage, fibrosis, and HCC development.
The suppression of STAT3 activation in the early stage of liver injury could be useful for preventing liver damage and fibrosis. We demonstrated that the adenoviral gene transfer of SOCS3 or dominant-negative STAT3 efficiently reduced hepatitis and fibrosis ( Figure 5) . Recently, the administration of cell-penetrating forms of SOCS3 (CP-SOCS3) into mice has been shown to counteract enterotoxin B and lipopolysaccharide and ConA-induced liver damage and inflammation (Jo et al., 2005) . Although these researchers did not examine fibrosis, since they used only acute inflammation models, a similar approach using cell-penetrating SOCS3 could be useful for preventing liver fibrosis. Similarly, suppression of STAT3 activity could be useful for preventing not only viral hepatitis-induced liver fibrosis but also HCC development. The induction of SOCS3 in the liver could also be effective, since SOCS3 expression can be induced in many ways, such as the elevation of cAMP (Boer et al., 2002) and the administration of statins (Huang et al., 2003) . In conclusion, this study provides the basis for the therapeutic potential of liver fibrosis through the STAT3 antagonists.
Materials and methods
Patients, samples, and fibrosis score Liver samples, primary HCC samples, and adjacent noncancerous tissues were obtained during partial hepatic resection surgery on patients at Kyushu University. All of them had chronic hepatitis C, and all samples were collected with the informed consent of patients. The fibrosis scores (stages) of the livers of patients with chronic hepatitis C were evaluated by using the METAVIR scoring system (Bedossa and Poynard, 1996) .
Generation of conditional SOCS3-deficient mice SOCS3 flox/flox (SOCS3 fl/fl ) mice were as described (Yasukawa et al., 2003) . To delete SOCS3 in the liver, SOCS3 fl/fl mice were i.v. injected with 1 Â 10 9 pfu of AdCre. In some experiments, Albumin-Cre (AlbCre) mice (Jakson Lab) expressing Cre recombinase under the control of the mouse albumin gene regulatory region (Postic and Magnuson, 2000) were crossed to SOCS3 fl/fl mice and used to isolate SOCS3-deficient hepatocytes. Genotyping was carried out with primers as described (Yasukawa et al., 2003) .
Induction of fibrosis in mice
For the liver fibrosis model, 10-week-old mice were administered DMN and ConA. For the fibrosis model, mice were i.p. injected with DMN (3.0 mg/g body weight) for 3 consecutive days each week for 7 weeks. The administration of DMN was adjusted weekly for body weight. After 2 days from the seventh series of injections, venous blood was collected, and the mice were killed. For ConA-induced fibrosis models, mice were i.v. injected with ConA (10 mg/g body weight) weekly for 4 weeks.
SOCS3 regulates hepatic fibrosis and TGF-b1
H Ogata et al At 1 day after the last injection, venous blood was collected, and the mice were killed. All experiments on these mice were approved by and performed in accordance with the Guidelines of the Animal Ethics Committee of Kyushu University, Fukuoka, Japan.
Recombinant adenovirus
Adenoviral vectors containing the genes for LacZ (AdLacZ), Myc-tagged SOCS3 (AdSOCS3) and HA-tagged Y705F dnSTAT3 (AddnSTAT3), and Cre (AdCre) were prepared by homologous recombination in HEK293 cells as described previously (Shouda et al., 2001) . For the in vivo gene transfer for the overexpression study, 200 ml of 5 Â 10 9 pfu/ml recombinant viruses in PBS was i.v. injected into C57BL/6 mice. Mice were i.p. injected with DMN (3.0 mg/g body weight) for 3 consecutive days per week and i.v. injected with the adenoviral vectors at 4 weeks after the initial DMN administration. After an additional 3 weeks of DMN administration, the mice were killed and examined.
Isolation and culture of primary hepatocytes Primary hepatocytes were prepared using the two-step collagenase perfusion method as described (Bissell et al., 1995) . After isolation, the cells were washed twice in Williams' E medium with 10% fetal bovine serum, L-glutamine, 100 nM dexamethasone, and 1 mM insulin. The cells were centrifuged at 50 g for 1 min between washes. Cell viability, as estimated by trypan blue exclusion, was routinely more than 97%. The cells were plated on collagen type I-coated plates at 3 Â 10 6 cells/ 100-mm dish and incubated for 10 h. For each experiment, cells were stimulated with IL-6 (100 ng/ml, Calbiochem). Parenchymal cells (hepatocytes) and nonparenchymal cells (stellate cells, Kupffer cells, and sinusoidal endothelial cells) were isolated separately from liver, as described previously (Bissell et al., 1995) .
Western blot analysis
Liver tissues obtained from mice treated with DMN and patients with chronic hepatitis were immediately frozen in liquid nitrogen and stored at À801C. The whole liver of mice and hepatic resection specimens of human patients were prepared as described (Yoshida et al., 2002) . The total cell extracts were resolved by SDS-PAGE, and membranes were immunoblotted with anti-phospho-STAT3 (Tyr705) (pY-STAT3), anti-phospho-STAT1 (Tyr701) (pY-STAT1), anti-phospho-ERK1/2 (Thr202/Tyr204) (p-ERK1/2) (Cell Signaling), anti-STAT3, anti-STAT1, anti-ERK2 (Santa Cruz), and polyclonal anti-SOCS3 (Immuno-Biological Laboratories). A macrophage cell line (RAW) stimulated with LPS for 3 h in vitro was used as a positive control. For quantitative analysis, the density of the blots for phosphorylated STAT3 and total STAT3 was measured and expressed as the ratio of phosphorylated STAT3 to total STAT3. In addition, the density of the blots for phosphorylated STAT1, phosphorylated ERK1/2, total STAT1, and total ERK2 was measured and expressed as the ratios of phosphorylated STAT1 and phosphorylated ERK1/2 to total STAT1 and total ERK2, respectively.
Immunohistochemistry and Sirius red staining
Liver tissues were fixed with 10% formalin, paraffin-embedded, and sectioned. Slides were incubated with either a 1:100 dilution of anti-phospho-STAT3-specific antibodies (anti-pY-STAT3; Cell Signaling) or a 1:100 dilution of polyclonal anti-SOCS3 (Immuno-Biological Laboratories), anti-TGF-b1 (Promega), or anti-a-smooth muscle actin (SMA) (Dako) and stained with the LSAB kit according to the manufacturer's instructions (Dako). The samples were then lightly stained with hematoxylin and examined. Liver fibrosis was quantified with Sirius red (Polyscience Inc.) staining as described . The sections were incubated for 10 min in an aqueous solution of saturated picric acid containing 0.1% Sirius red. Red-stained collagen fibers were quantitated by digital image analysis .
RNA extraction and real-time RT-PCR Total RNAs from mice livers and primary hepatocytes were prepared using the TRIZOL reagent (Invitrogen). RT-PCR was carried out using the one-step RT-PCR kit (Applied Biosystems) according to the manufacturer's instructions. Quantitative real-time RT-PCR was monitored using the ABI PRISM 7700 (PE Applied Biosystems), and the results were analysed with the accompanying software, as described (Kimura et al., 2004) . The SYBR Green PCR Master Mix was used for the detection of mouse SOCS1, SOCS3, and human TGF-b1. The primer pairs are described below; the primer sets were 5 0 -GAAGCCATCTTCACGCTG-3 0 and 5 0 -ACACTCA CTTCCGCACCTTC-3 0 (mouse SOCS1); 5 0 -GGGTGGCA AAGAAAAGGAG-3 
Statistical analysis
The results are expressed as the mean7s.e.m. Each piece of data was analysed using an unpaired two-tailed Student's t-test and analysis of variance (ANOVA).
Abbreviations JAK, Janus kinase; STAT, signal transducers and activators of transcription; SOCS, suppressor of cytokine signaling; TGF, transforming growth factor; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
